AtriCure, Inc. (ATRC) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-16

Key Insights

Vinayak Doraiswamy, the Chief Scientific Officer of AtriCure, Inc., sold 5,000 shares of the company's common stock at an average price of $29.83 per share.
This transaction represents a small portion of Doraiswamy's overall beneficial ownership, which remains at 96,875 shares following the reported sale.
Insider selling can sometimes signal management's views on the company's future prospects, but a single transaction of this size is not necessarily a significant event on its own.

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-12

The reporting person, Robert S. White, has exercised 10,000 non-qualified stock options in AtriCure, Inc. (ATRC) at an exercise price of $14.99 per share.
The exercise of these options has increased White's direct beneficial ownership of ATRC common stock to 122,174 shares.
The exercise of these options was made pursuant to a contract, instruction or written plan, suggesting a planned transaction.

Filed: 2026-03-09

The reporting person, Michael H. Carrel, who is the President, CEO, and Director of AtriCure, Inc., has made two separate gifts of 5,000 and 1,000 shares of the company's common stock to his children and sibling, respectively.
Carrel continues to hold a significant direct ownership stake in AtriCure, with 778,498 shares, and also has indirect beneficial ownership of an additional 17,560 shares through his children and parents.
The reporting of these insider transactions provides insight into Carrel's confidence in the company and his alignment with shareholder interests through his personal holdings.

Filed: 2026-01-02

Douglas J. Seith, the Chief Operating Officer of AtriCure, Inc. (ATRC), acquired 257 shares of the company's common stock through the 2018 Employee Stock Purchase Plan on December 31, 2025.
The shares were purchased at a discounted price of $27.37 per share, which is 85% of the closing price on the first trading day of the applicable offering period.
This insider purchase suggests Seith's confidence in the company's outlook and aligns his interests with those of shareholders.

Other reports for AtriCure, Inc.

Quarterly Report Annual Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.